Schleuning M, Munker R
Medizinische Klinik III, Universitätsklinikum Grosshadern, München.
Klin Wochenschr. 1990 Sep 3;68(17):841-6. doi: 10.1007/BF01662779.
Tumor necrosis factor is one of the recently cloned cytokines with pleiotropic effects on normal and malignant cells. Our knowledge about the scope of cells producing or responding to this cytokine has enormously expanded. In critically ill patients with acute hepatic failure, acute graft-versus-host disease, or septic shock, circulating tumor necrosis factor can be measured and useful prognostic correlations do exist. Despite promising in vitro results, early clinical trials with tumor necrosis factor for the treatment of cancer have failed thus far to reveal major antineoplastic activity in cancer patients. However, more clinical trials are necessary, since different routes of administration and combinations with other cytokines may lead to favorable results.
肿瘤坏死因子是最近克隆出的对正常细胞和恶性细胞具有多效性作用的细胞因子之一。我们对产生或响应这种细胞因子的细胞范围的了解已大大扩展。在患有急性肝衰竭、急性移植物抗宿主病或感染性休克的重症患者中,可以检测到循环肿瘤坏死因子,并且确实存在有用的预后相关性。尽管体外实验结果很有前景,但迄今为止,用肿瘤坏死因子治疗癌症的早期临床试验未能在癌症患者中显示出主要的抗肿瘤活性。然而,由于不同的给药途径以及与其他细胞因子的联合使用可能会产生良好的效果,因此需要进行更多的临床试验。